CB
Therapeutic Areas
OmniAb Pipeline
| Drug | Indication | Phase |
|---|---|---|
| JNJ-81201887 (via Janssen) | Plaque Psoriasis | Approved |
| LN-144 (via Iovance) | Advanced Melanoma | BLA Submitted |
| Multiple Partner Programs | Various (Oncology, Immunology, etc.) | Phase I to Phase III |
Leadership Team at OmniAb
MW
Matthew W. Foehr
Chief Executive Officer & President
KG
Kurt Gustafson
Chief Financial Officer
YA
Yasmina Abdiche, PhD
Senior Vice President, Exploratory Research
CR
Carolyn R. Bertozzi, PhD
Board Chair
JC
Jennifer Cochran, PhD
Board Member
SC
Steve Crouse
Board Member